search
Back to results

Evaluation of the Safety of the Medical Device Simeox® (SIMETOL)

Primary Purpose

Broncho-degenerative Disease, Chronic Obstructive Airway Disease, Cystic Fibrosis

Status
Terminated
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Simeox
Physiotherapy
Sponsored by
Physio-Assist
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Broncho-degenerative Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient over 18, male or female.
  • Patient affected by broncho-degenerative disease, chronic obstructive airway disease, cystic fibrosis, idiopathic bronchiectasis, ciliary dyskinesia and/or chronic bronchitis.
  • Hospitalization for a minimum of five days or a maximum of 8 days.
  • Bronchial clearance is usually productive.
  • FVC and / or FEV <85% predicted, with stable lung function.
  • Agreement to participate to the study and signature of the informed consent form
  • Social security coverage.

Exclusion Criteria:

  • Patient infected with bacteria resistant to antibiotics.
  • Bronchial clearance is not usually productive.
  • Patient with contra-indication for physiotherapy bronchial clearance.
  • Patient who received a lung transplant.
  • Care requires more than 2 sessions of chest physiotherapy daily.
  • Duration of mechanical ventilation > 8h/day.
  • Patient with an episode of hemoptysis during the month before inclusion.
  • Patient with an episode of pneumothorax during the last month.
  • Pregnant or lactating women.
  • Patient with a disability and/or unwillingness to follow protocol requirements.
  • Patient participating in another clinical study or having tested an experimental drug within 30 days prior to his inclusion in the study.
  • Patient ( s) with another condition which, according to the investigator , may interfere with the result or conduct of the trial and thus justify their non- inclusion in the study.

Sites / Locations

  • CHU Nord

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Physiotherapy

simeox

Arm Description

Traditional techniques

Medical device

Outcomes

Primary Outcome Measures

Safety of the simeox®
Adverse events related or not to the simeox®

Secondary Outcome Measures

Full Information

First Posted
January 31, 2014
Last Updated
October 16, 2019
Sponsor
Physio-Assist
Collaborators
CEISO, University Hospital, Marseille
search

1. Study Identification

Unique Protocol Identification Number
NCT02061852
Brief Title
Evaluation of the Safety of the Medical Device Simeox®
Acronym
SIMETOL
Official Title
Prospective Trial for the Evaluation of Safety, Tolerability and Efficacy of the Medical Device Simeox ® Compared to Traditional Respiratory Physiotherapy Techniques for Airway Secretion Clearance
Study Type
Interventional

2. Study Status

Record Verification Date
October 2019
Overall Recruitment Status
Terminated
Study Start Date
July 2014 (undefined)
Primary Completion Date
September 2015 (Actual)
Study Completion Date
September 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Physio-Assist
Collaborators
CEISO, University Hospital, Marseille

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine whether the medical device "simeox" is safe in the treatment of respiratory diseases, in comparison with traditional physiotherapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Broncho-degenerative Disease, Chronic Obstructive Airway Disease, Cystic Fibrosis, Idiopathic Bronchiectasis, Ciliary Dyskinesia, Chronic Bronchitis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
15 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Physiotherapy
Arm Type
Active Comparator
Arm Description
Traditional techniques
Arm Title
simeox
Arm Type
Experimental
Arm Description
Medical device
Intervention Type
Device
Intervention Name(s)
Simeox
Intervention Type
Procedure
Intervention Name(s)
Physiotherapy
Primary Outcome Measure Information:
Title
Safety of the simeox®
Description
Adverse events related or not to the simeox®
Time Frame
Day 8

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient over 18, male or female. Patient affected by broncho-degenerative disease, chronic obstructive airway disease, cystic fibrosis, idiopathic bronchiectasis, ciliary dyskinesia and/or chronic bronchitis. Hospitalization for a minimum of five days or a maximum of 8 days. Bronchial clearance is usually productive. FVC and / or FEV <85% predicted, with stable lung function. Agreement to participate to the study and signature of the informed consent form Social security coverage. Exclusion Criteria: Patient infected with bacteria resistant to antibiotics. Bronchial clearance is not usually productive. Patient with contra-indication for physiotherapy bronchial clearance. Patient who received a lung transplant. Care requires more than 2 sessions of chest physiotherapy daily. Duration of mechanical ventilation > 8h/day. Patient with an episode of hemoptysis during the month before inclusion. Patient with an episode of pneumothorax during the last month. Pregnant or lactating women. Patient with a disability and/or unwillingness to follow protocol requirements. Patient participating in another clinical study or having tested an experimental drug within 30 days prior to his inclusion in the study. Patient ( s) with another condition which, according to the investigator , may interfere with the result or conduct of the trial and thus justify their non- inclusion in the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Martine Reynaud-Gaubert, Prof.
Organizational Affiliation
Hospital Marseille
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU Nord
City
Marseille
ZIP/Postal Code
13915 Cedex 20
Country
France

12. IPD Sharing Statement

Learn more about this trial

Evaluation of the Safety of the Medical Device Simeox®

We'll reach out to this number within 24 hrs